Plasma-SeqSensei™ Kits
Ultra-sensitive NGS liquid biopsy kit solutions
With more than 10 years of experience in liquid biopsy, Sysmex Inostics is propelling liquid biopsy solutions forward with a new next-generation sequencing-based assay: the Plasma-SeqSenseiTM IVD* and RUO** kits.
Built on ultra-sensitive Plasma-Safe-SeqS technology, the new Plasma-SeqSenseiTM kit portfolio detects and identifies mutations in various genes in human circulating cell-free DNA isolated from blood plasma.
Plasma-SeqSenseiTM kits provide narrow panels with ultra-high sensitivity down to 0.06% mutant allele fractions (MAF) and absolute limit detection of 6 mutant molecules (MM) which is important for the clinical research purpose such as response monitoring, recurrence monitoring, and minimal residual disease detection.
*Currently only available in EMEA region.
**For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer.
Citations
*Currently only available in EMEA region
**For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer
Unique Benefits
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
- Highly sensitive
- Detects 0.06% and higher MAF with 95% certainty (in a background of 10,000 wildtype copies)
- Determines mutant molecules (MM) down to a limit of detection of 6 (independent of real sample DNA input)
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
- Absolute quantification of samples using internal quantifier
- Usage of UIDs (unique molecular identifiers)
- Reduces error reporting rate over 100-fold
- Standardized workflow and high reproducibility
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
- High flexibility and efficiency
- Processes 2 to 16 samples per run
- Pools multiple PSS RUO libraries in one run to save time and sequencing costs (not available for IVD kits)
- Short turnaround time
- Takes ~2 days for 16 samples from DNA extraction to results (including sequencing time)
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
- Easy-to-use and convenient Plasma-SeqSenseiTM Software
- Integrates run-planning feature
- Provides sample variant call file, including validity checks for sample results
- Automates data analysis and generation of PDF-report per sample
Plasma-SeqSensei™
Solid Cancer IVD kit
Highly sensitive detection and identification of mutations in BRAF, EGFR, KRAS, NRAS and PIK3CA genes associated with development of solid cancer.
Learn More Technical Information & Software
Plasma-SeqSensei™
Breast Cancer IVD kit
Highly sensitive detection and identification of mutations in AKT1, ERBB2, ESR1, KRAS, PIK3CA and TP53 genes associated with development of breast cancer.
Learn More Technical Information & Software
Plasma-SeqSensei™
CRC RUO kit
Highly sensitive detection and identification of mutations in KRAS, NRAS, BRAF, and PIK3CA genes associated with colorectal cancer.
Learn More
Plasma-SeqSensei™
BC RUO kit
Highly sensitive detection and identification of mutations in AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 genes associated with breast cancer.
Learn More
Plasma-SeqSensei™
NSCLC RUO kit
Highly sensitive detection and identification of mutations in BRAF, EGFR, KRAS, and PIK3CA genes, which play a significant role in the development of NSCLC.
Learn More
Plasma-SeqSensei™
Melanoma RUO kit
Highly sensitive detection and identification of mutations in BRAF and NRAS oncogenes associated with melanoma development.
Learn More
Plasma-SeqSensei™
Thyroid RUO kit
Highly sensitive detection and identification of mutations in hotspot regions of BRAF and NRAS genes associated with thyroid cancer.
Learn More